Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Will I gain the weight back when I stop GLP-1 therapy
Practical Diabetes International
The SELECT trial establishing semaglutides 20% reduction in major adverse cardiovascular events has converted GLP-1 receptor agonists from single-indication obesity drugs into foundational chronic disease therapeutics demanding continuous prescription renewal
Nutritional and botanical interventions, including bitter herbs, omega-3 fatty acids and targeted nutrient balance offer evidence-based alternatives to GLP-1 drugs, as well as opportunities to support those patients already using GLP-1 medications in mitigating side effects and augmenting their results
Hyper-restrictive diets aren't necessary or recommendedGLP-1 naturally reduces appetite
